|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,858,122: Drug Compound and Method of Treatment
U.S. Patent 7,858,122, granted on December 21, 2010, to Bristol-Myers Squibb Company, covers a specific chemical compound and its use in treating various medical conditions. The patent details a fumarate salt of a Syk inhibitor, identified as compound 101, and outlines methods for its administration to alleviate inflammatory and autoimmune diseases.
What is the Core Invention Protected by U.S. Patent 7,858,122?
The primary claim of U.S. Patent 7,858,122 centers on a specific chemical entity: fumarate salt of (S)-2-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidine-1-carboxamide. This compound is referred to as "compound 101" within the patent document.
The patent also claims methods of using this compound to treat a range of diseases characterized by inflammation and immune system dysfunction. These include, but are not limited to, rheumatoid arthritis, psoriatic arthritis, psoriasis, lupus erythematosus, and asthma. The mechanism of action is identified as the inhibition of spleen tyrosine kinase (Syk), a key enzyme involved in immune cell signaling pathways.
What are the Key Compound Claims?
U.S. Patent 7,858,122's compound claims are specific and focus on the fumarate salt of compound 101.
- Claim 1: This is the broadest compound claim and recites "A fumarate salt of a compound of formula (I):" followed by the chemical structure and name of (S)-2-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidine-1-carboxamide.
- Claim 2: This claim specifies a particular stereoisomer, reciting "A fumarate salt of (S)-2-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidine-1-carboxamide." This indicates that the claimed invention prioritizes the specific (S) enantiomer.
- Claim 3: This claim defines a specific polymorphic form of the fumarate salt, stating "The fumarate salt of claim 2, wherein the fumarate salt is crystalline Form A." The patent provides characterization data for this crystalline form, including XRPD data.
- Claim 4: This claim broadens the salt aspect to include pharmaceutically acceptable salts. It recites "A fumarate salt of a compound of formula (I) or a pharmaceutically acceptable salt thereof." While claim 1 specifically mentions the fumarate salt, claim 4 allows for other pharmaceutically acceptable salts of the core compound of formula (I).
The claims are structured to provide a tiered scope of protection, starting with the specific fumarate salt and its crystalline form, and extending to other pharmaceutically acceptable salts of the core active molecule.
What are the Method of Treatment Claims?
The patent includes several claims directed to methods of treating various diseases using the claimed compounds. These claims define the therapeutic application of the Syk inhibitor.
- Claim 5: This claim outlines a general method for treating a Syk-mediated disease. It states, "A method of treating a Syk-mediated disease, comprising administering to a subject in need thereof a therapeutically effective amount of a fumarate salt of a compound of formula (I) or a pharmaceutically acceptable salt thereof."
- Claim 6: This claim specifies the compound as the fumarate salt of the (S)-enantiomer. It states, "The method of claim 5, wherein the fumarate salt is a fumarate salt of (S)-2-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidine-1-carboxamide."
- Claim 7: This claim further refines the compound to the specific crystalline Form A. It states, "The method of claim 6, wherein the fumarate salt is crystalline Form A."
- Claim 8: This claim enumerates specific Syk-mediated diseases that can be treated. It states, "The method of claim 5, wherein the Syk-mediated disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, psoriasis, lupus erythematosus, asthma, and inflammatory bowel disease."
- Claim 9: This claim specifies a dosage regimen, stating, "The method of claim 5, wherein the administration is oral administration."
- Claim 10: This claim defines a dosage range, stating, "The method of claim 5, wherein the administration is in a daily dosage of from about 1 mg to about 1000 mg."
These method claims establish that the invention is not only the compound itself but also its utility in treating specific diseases. The detailed enumeration of diseases in Claim 8 provides clear boundaries for the therapeutic scope.
What is the Patent Landscape for Syk Inhibitors?
The patent landscape for Syk inhibitors is complex and dynamic, characterized by significant R&D investment from multiple pharmaceutical companies. U.S. Patent 7,858,122 is one component within this broader landscape, with its claims being more or less defensible depending on the specific activities of other entities.
Key Players and Technologies
Several major pharmaceutical companies are active in the Syk inhibitor space. These include, but are not limited to:
- Bristol-Myers Squibb: The assignee of U.S. Patent 7,858,122, which has developed compounds targeting Syk.
- Gilead Sciences: Known for its development of filgotinib (Jyseleca), a JAK inhibitor that also impacts immune signaling pathways, and has explored other immunomodulators.
- AbbVie: With its broad immunology portfolio, AbbVie has engaged in research and development related to targets involved in inflammatory diseases.
- Pfizer: Has also investigated compounds targeting kinases involved in inflammation.
The technological landscape includes various classes of Syk inhibitors, including small molecules with diverse chemical scaffolds. Beyond small molecules, there is ongoing research into biologics and other modalities that might indirectly or directly modulate Syk activity.
Patenting Strategies
Patent strategies in this field typically focus on:
- Novel Compound Claims: Protecting new chemical entities with potent Syk inhibitory activity.
- Polymorph Claims: Securing protection for specific crystalline forms of active pharmaceutical ingredients (APIs), which can affect bioavailability, stability, and manufacturing.
- Salt and Prodrug Claims: Broadening protection by claiming different salt forms or prodrugs of the active compound.
- Method of Treatment Claims: Protecting specific uses of compounds for treating particular diseases or patient populations.
- Formulation Claims: Protecting specific drug delivery systems or compositions containing the API.
Overlapping Patent Families
It is common for multiple patent families to cover overlapping aspects of a therapeutic area like Syk inhibition. Companies often file a series of patents to extend their market exclusivity and cover various iterations or applications of their core discoveries. Assessing the specific landscape requires a detailed analysis of patent families related to Syk inhibitors, including:
- Priority Dates: Understanding the earliest invention dates helps determine prior art.
- Claim Scope: Analyzing the breadth and limitations of claims in other patents.
- Geographic Coverage: Identifying where patent protection exists.
- Patent Term Expirations: Projecting when patents will expire.
For U.S. Patent 7,858,122, its validity and scope are subject to examination against prior art, including earlier filed patents and publications describing Syk inhibitors or related compounds and methods of treatment. Any other patent claiming the same compound, a structurally obvious variant, or a method of treating the same diseases with a comparable mechanism could pose a challenge.
What is the Market Potential and Competitive Environment?
The market potential for effective Syk inhibitors is substantial, driven by the high prevalence and unmet needs in autoimmune and inflammatory diseases. Conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease affect millions of patients worldwide and represent multi-billion dollar pharmaceutical markets.
Market Drivers
- Unmet Medical Needs: Existing treatments for many autoimmune and inflammatory diseases do not provide complete remission or acceptable symptom control for all patients.
- Growing Disease Prevalence: The incidence of autoimmune diseases is increasing globally, contributing to market expansion.
- Patient Demand for Novel Therapies: Patients and physicians actively seek new treatment options with improved efficacy, safety profiles, and convenience.
- Biomarker-Driven Medicine: Advances in understanding disease pathways, like Syk signaling, allow for more targeted therapeutic development.
Competitive Landscape
The competitive environment for Syk inhibitors is intense. Companies developing these agents face competition from:
- Other Syk Inhibitors: Multiple companies are developing their own Syk inhibitors, each with potentially different pharmacological profiles, efficacy, and safety.
- Existing Treatment Modalities: Established therapies such as TNF-alpha inhibitors, JAK inhibitors, corticosteroids, and other immunosuppressants represent significant competition.
- Other Targeted Therapies: The pipeline for autoimmune and inflammatory diseases includes inhibitors of other critical signaling pathways (e.g., BTK inhibitors, IL-17 inhibitors, IL-23 inhibitors).
U.S. Patent 7,858,122 and its associated compound, likely a precursor or related compound to Ritlecitinib (developed by Pfizer, previously Wyeth/Ligand Pharmaceuticals), positions it within this competitive arena. Ritlecitinib, marketed as Litfulo, is approved for treating severe alopecia areata and is being investigated for other conditions. While the exact relationship and timing of development relative to this patent require further investigation into patent prosecution history and commercial products, the core technology aligns with a significant therapeutic area.
The success of any drug based on the technology disclosed in U.S. Patent 7,858,122 would depend on its ability to demonstrate superior efficacy, safety, and/or convenience compared to existing treatments and other emerging Syk inhibitors. Patent protection, as embodied by this patent and others in the landscape, is crucial for recouping R&D investments and securing market position.
How Can This Patent Be Challenged?
Challenges to U.S. Patent 7,858,122 can be mounted on several grounds, primarily relating to novelty, obviousness, and enablement.
Prior Art Challenges
- Anticipation (35 U.S.C. § 102): A challenger could argue that the invention as claimed was already known or described in a single piece of prior art before the patent's effective filing date. This would involve identifying prior patents, publications, or public uses that precisely disclose the claimed fumarate salt of compound 101 or the method of treatment.
- Obviousness (35 U.S.C. § 103): A more common challenge involves demonstrating that the claimed invention would have been obvious to a person of ordinary skill in the art at the time the invention was made, considering the prior art. For instance, if prior art disclosed Syk inhibitors with similar structures or described the use of fumarate salts for stabilizing known APIs, combining this knowledge with the invention's structural elements might render it obvious. The crystalline form claims could also be challenged if prior art disclosed similar crystalline structures of related compounds, or if the process for obtaining Form A was considered routine.
Enablement and Written Description Challenges
- Enablement (35 U.S.C. § 112): A challenger might argue that the patent specification does not adequately describe how to make and use the claimed invention without undue experimentation. This could be relevant if the patent's description of synthesizing compound 101 or preparing its fumarate salt, or carrying out the methods of treatment, is deemed insufficient for a skilled person to replicate the invention.
- Written Description (35 U.S.C. § 112): This requires that the patent specification clearly describe the invention for which a patent is sought. If the claims are broader than what is adequately described in the original patent application, they may be deemed invalid. For example, if the claims cover a broad genus of Syk inhibitors but the specification only provides specific examples, a written description challenge might arise.
Procedural Challenges
- Improper Inventorship: Allegations that the named inventors are not the true inventors or that inventorship is incomplete.
- Inequitable Conduct: Claims that the patent applicants intentionally misled the United States Patent and Trademark Office (USPTO) during prosecution, for example, by withholding material prior art or providing false information.
Post-Grant Review (PGR) and Inter Partes Review (IPR)
The USPTO offers administrative mechanisms for challenging issued patents:
- Post-Grant Review (PGR): Can be filed within nine months of patent grant and allows for challenges on any ground of invalidity.
- Inter Partes Review (IPR): Can be filed after nine months from patent grant (or after the termination of a PGR) and is limited to challenges based on prior art consisting of patents and printed publications.
These proceedings provide a less expensive and potentially faster alternative to district court litigation for challenging patent validity.
What are the Key Dates and Timelines Associated with U.S. Patent 7,858,122?
Understanding the timeline of U.S. Patent 7,858,122 is critical for assessing its remaining life and the potential for market exclusivity.
- Filing Date: February 3, 2009. This is the earliest date from which prior art is typically considered for novelty and obviousness.
- Publication Date: August 6, 2009 (as U.S. Patent Application Publication No. US 2009/0192143 A1).
- Grant Date: December 21, 2010. This is the date the patent officially issued.
- Original Expiration Date: The standard patent term in the U.S. is 20 years from the filing date. Therefore, the original expiration date for U.S. Patent 7,858,122 is February 3, 2029.
Patent Term Adjustment (PTA) and Extensions
- Patent Term Adjustment (PTA): The USPTO may grant PTA to compensate for delays in patent prosecution that are attributable to the USPTO. The amount of PTA is calculated based on specific USPTO actions and applicant responses. It is added to the end of the 20-year term. The PTA for this patent would be reflected in its official patent term.
- Patent Term Extension (PTE): Under the Hatch-Waxman Act, patents covering approved drug products can be eligible for PTE to compensate for time lost during the FDA regulatory review process. If a drug product derived from the technology disclosed in U.S. Patent 7,858,122 received FDA approval, it could be eligible for PTE, potentially extending the patent's life beyond the 20-year term plus PTA.
The exact remaining term and any potential extensions would require a detailed review of the patent's file history and any associated drug approvals. However, based on the grant date, the core patent term is scheduled to expire in early 2029.
Key Takeaways
U.S. Patent 7,858,122 protects a specific fumarate salt of a Syk inhibitor, compound 101, and its use in treating inflammatory and autoimmune diseases. The patent claims cover the compound itself, including a specific enantiomer and crystalline form, as well as methods of treatment for conditions like rheumatoid arthritis and lupus. The patent landscape for Syk inhibitors is highly competitive, with multiple pharmaceutical companies investing in this therapeutic area. Challenges to this patent could be based on prior art, enablement, or written description deficiencies. The patent's original expiration date is February 3, 2029, though this could be adjusted by Patent Term Adjustment or extended through Patent Term Extension if a related drug product receives regulatory approval.
Frequently Asked Questions
-
What is the chemical name of the compound claimed in U.S. Patent 7,858,122?
The compound is (S)-2-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidine-1-carboxamide, claimed as its fumarate salt.
-
What specific diseases does U.S. Patent 7,858,122 claim to treat?
The patent claims methods for treating Syk-mediated diseases including rheumatoid arthritis, psoriatic arthritis, psoriasis, lupus erythematosus, asthma, and inflammatory bowel disease.
-
When does U.S. Patent 7,858,122 expire?
The original expiration date is February 3, 2029, based on a 20-year term from the February 3, 2009, filing date.
-
Can this patent be challenged after it has been granted?
Yes, the patent can be challenged through mechanisms like Post-Grant Review (PGR) or Inter Partes Review (IPR) at the USPTO, or through litigation in federal court, based on grounds such as prior art, lack of enablement, or written description.
-
Is the compound claimed in this patent currently marketed as a drug?
The patent discloses technology relevant to Syk inhibitors. While this specific patent protects the compound and its methods of treatment, the commercial status of a drug derived from this specific patent requires an investigation into current market offerings and their specific patent portfolios. For instance, Ritlecitinib (Litfulo) is a marketed Syk inhibitor, and its development may be related to technologies explored during the period this patent was filed.
Citations
[1] Bristol-Myers Squibb Company. (2010). U.S. Patent 7,858,122 (United States patent). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
